历经9个月等待,投资者等来的并不是复牌信息,而是两则核心高层变动公告标点财经、投资时间网研究员 李路2024年的医药行业中,有十多家上市药企因信息披露违法违规被证监会立案,甚至有些企业受到了行政处罚。例如广誉远(600771.SH)因2016年至2021年年报“买断式销售”模式披露不真实受到处罚,康美药业(600518.SH)因2016年至2018年连续三年实施财务造假约300亿元遭到监管处罚,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.